Stelara 130 MG/26 ML vial 26ML
Ended Awarded
- Contract number
- SPE2DR26FCRE3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $7,731
Award facts
- Contract value 100% obligated
- $7,730.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $7,730.52 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Stelara 130 mg/26 mL vials. The delivery order, issued on October 24, 2025, with an ultimate completion date of November 17, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award represents one of numerous delivery orders issued to DMS Pharmaceutical Group under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to supply pharmaceutical products and medical consumables to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract under the PPV-G GEN V program (Contract SPE2DR) valued at $499,999,999, effective through December 31, 2036, with a 30-month base period and three 30-month option periods. The contract authorizes the Defense Logistics Agency to issue delivery orders for branded and generic prescription medications, biologics, vaccines, and medical consumables to support the recurring medical supply needs of military healthcare operations globally. The vendor's established performance across multiple therapeutic categories and product lines, combined with its small business status, positions DMS Pharmaceutical Group as a critical supplier within the federal pharmaceutical supply chain serving Department of Defense healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FCRE3?
SPE2DR26FCRE3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 24, 2025.
How much is contract SPE2DR26FCRE3 worth?
The government has obligated $7,731 on SPE2DR26FCRE3.
Is contract SPE2DR26FCRE3 an order under another contract?
Yes. SPE2DR26FCRE3 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRE3 competed?
The extent of competition for SPE2DR26FCRE3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award